
==== Front
BMJ OpenBMJ OpenbmjopenbmjopenBMJ Open2044-6055BMJ Publishing Group BMA House, Tavistock Square, London, WC1H 9JR bmjopen-2018-026590corr110.1136/bmjopen-2018-026590corr1Correction1506Correction: The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial
 2019 1 6 2019 1 6 2019 9 5 e026590corr1© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.2019This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.special-featureunlockedaccess-typefree
==== Body
Ejiri K, Miyoshi T, Nakamura K, et al. The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial. BMJ Open 2019;9:e026590. doi: 10.1136/bmjopen-2018-026590.

This article was previously published with an error.

Under ‘Finding’ section, the authors have stated, “This study is funded by Novartis Pharmaceuticals (Basel, Switzerland).”

The correct sentence is as follows:

“This study is funded by Novartis Pharma K. K.”

